Lupin Launches World's First Triple Combo MDI for COPD in India
Lupin Limited has launched Formoflo-G® MDI, the world's first fixed-dose triple combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD) in India. This launch follows approval from the Drug Controller General of India (DCGI) and marks a significant advancement in respiratory care. Formoflo-G® combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate for the long-term management of moderate to severe COPD. The product is designed for twice-daily use and aims to provide a more accessible and effective treatment option for the over 55 million people living with COPD in India. Lupin, already a strong player in the respiratory segment, aims to improve patient outcomes with this innovative therapy.
Key Highlights
- Lupin launches Formoflo-G® MDI, a novel triple combination for COPD.
- It is the world's first fixed-dose MDI of its kind for COPD management.
- The drug combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate.
- Launch targets over 55 million COPD patients in India.
- Strengthens Lupin's leadership in the respiratory therapy segment.
Price Impact
More from LUPIN